Clinical Pharmacists' Practice in the Treatment of Tislelizumab-Induced Toxic Epidermal Necrolysis:A Case Report
Objective To provide a reference for the safe use of tislelizumab in clinical practice.Methods The clinical diagnosis and treatment process of a lung cancer patient who experienced toxic epidermal necrolysis(TEN)was retrospectively analyzed.The clinical pharmacists assisted the physicians in identifying the suspected drug based on the patient's medication history,drug instructions and relevant literature.The correlation between the adverse drug reaction(ADR)and the use of tislelizumab was evaluated by the Naranjo's ADR evaluation scale and algorithm of drug causality for epidermal necrolysis(ALDEN),and the medication regimen was adjusted.TEN was possible or probable correlated with the use of tislelizumab,with scores of two and five points by the Naranjo's ADR evaluation scale and ALDEN,respectively.The clinical pharmacists suggested suspending the anti-tumor therapy,increasing the dosage of methylprednisolone from 40 mg/d to 100 mg/d,and giving the implosive therapy of gamma globulin for 3 d.Results The physicians adopted the suggestions,and the patient's skin lesions improved,exudation and pain obviously relieved.Conclusion When using tislelizumab,attention should be paid to the adverse skin reactions of patients(especially TEN),and corresponding intervention measures should be taken in a timely manner.
tislelizumabtoxic epidermal necrolysisadverse drug reactionclinical pharmacistpharmaceutical care
万方数据
维普
